[1] Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018[J]. CA Cancer J Clin, 2018, 68(1): 7-30. [2] Zucman-Rossi J, Villanueva A, Nault JC, et al. Genetic landscape and biomarkers of hepatocellular carcinoma[J]. Gastroenterology, 2015, 149(5): 1226-1239. [3] Revill K, Wang T, Lachenmayer A, et al. Genome-wide methylation analysis and epigenetic unmasking identify tumor suppressor genes in hepatocellular carcinoma [J]. Gastroenterology, 2013, 145(6): 1424-1435. [4] 杨 波, 卢学春, 刘丽宏, 等. 靶向上调ID4基因表达药物的生物信息学预测和初步验证 [J]. 中华医学杂志, 2009, 89(24): 1714-1716. [5] Yang B, Lu XC, Chi XH, et al. LRP16 gene function based on bioinformatic analysis [J]. Ai zheng, 2009, 28(12): 1283-1290. [6] 卢学春, 杨 波, 朱宏丽, 等. 生物信息学方法优化依硫磷酸联合方案治疗骨髓增生异常综合征的应用研究 [J]. 中华医学杂志, 2009, 89(26): 1834-1837. [7] 卢学春, 迟小华, 杨 波, 等. 重型再生障碍性贫血发病相关T淋巴细胞基因表达谱的生物信息学分析及作为药物筛选新方法的探索 [J]. 中国实验血液学杂志, 2010, 18(2): 416-420. [8] 杨 波, 蔡力力, 迟小华, 等. 依硫磷酸调控人类基因表达谱的预测及生物信息学分析 [J]. 中国实验血液学杂志, 2011, 19(3): 711-716. [9] 卢学春, 杨 波, 迟小华, 等. 含盐酸二甲双胍联合方案治疗再生障碍性贫血的短期疗效观察 [J]. 解放军医学杂志, 2012, 37(3): 229-233. [10]Yu R, Yang B, Chi X, et al. Efficacy of cytokine-induced killer cell infusion as an adjuvant immunotherapy for hepatocellular carcinoma: a systematic review and meta-analysis [J]. Drug Des Devel Ther, 2017, 11: 851-864. [11]于睿莉, 杨 波, 蔡力力, 等. 老年骨髓增生异常综合征的临床病理特征及氨磷汀联合造血生长因子方案的长期疗效观察 [J]. 中国药物应用与监测, 2017,14(2): 75-80. [12]中国癌症基金会《 中国肿瘤临床年鉴》编辑委员会编.2016中国肿瘤临床年鉴[M]. 中国协和医科大学出版社, 2017: 578-579. [13]Ghouri YA, Mian I, Rowe JH. Review of hepatocellular carcinoma: Epidemiology, etiology, and carcinogenesis[J]. J Carcinog, 2017, 16: 1. [14]李金龙, 陈三三, 张春华, 等. 细胞分裂周期蛋白6: 新的抗肿瘤靶点 [J]. 中国细胞生物学学报, 2013, 35(6): 857-862. [15]Xiong XD, Fang JH, Qiu FE, et al. A novel functional polymorphism in the Cdc6 promoter is associated with the risk for hepatocellular carcinoma[J]. Mutat Res, 2008, 643(1-2): 70-74. [16]Engelman JA. Targeting PI3K signalling in cancer: opportunities, challenges and limitations[J]. Nat Rev Cancer, 2009, 9(8): 550-562. [17]Kanamoto N, Tagami T, Ueda-Sakane Y, et al. Forkhead box A1 (FOXA1) and A2 (FOXA2) oppositely regulate human type 1 iodothyronine deiodinase gene in liver[J]. Endocrinology, 2012, 153(1): 492-500. [18]Steelman LS, Chappell WH, Abrams SL, et al. Roles of the Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR pathways in controlling growth and sensitivity to therapy-implications for cancer and aging[J]. Aging (Albany NY), 2011, 3(3): 192-222. [19]Philp AJ, Campbell IG, Leet C, et al. The phosphatidylinositol 3'-kinase p85alpha gene is an oncogene in human ovarian and colon tumors[J]. Cancer Res, 2001, 61(20): 7426-7429. [20]He S, Zhang J, Zhang W, et al. FOXA1 inhibits hepatocellular carcinoma progression by suppressing PIK3R1 expression in male patients[J]. J Exp Clin Cancer Res, 2017, 36(1): 175. [21]Liu Z, Ling K, Wu X, et al. Reduced expression of cenp-e in human hepatocellular carcinoma[J]. J Exp Clin Cancer Res, 2009, 28: 156. [22]Liu B, Luo H, Wu G, et al. Low expression of spindle checkpoint protein, Cenp-E, causes numerical chromosomal abnormalities in HepG-2 human hepatoma cells[J]. Oncol Lett, 2015, 10(5): 2699-2704. [23]何 平. RAC GTPase激活蛋白RACGAP1和滋养层糖蛋白TPBG在胰导管腺癌和肝癌中的作用研究及机制初探[M]. 上海交通大学, 译. 张志刚, 主编. 生物化学与分子生物学, 2015. [24]Imaoka H, Toiyama Y, Saigusa S, et al. RacGAP1 expression, increasing tumor malignant potential, as a predictive biomarker for lymph node metastasis and poor prognosis in colorectal cancer[J]. Carcinogenesis, 2015, 36(3): 346-354. [25]Kawashima T, Hirose K, Satoh T, et al. MgcRacGAP is involved in the control of growth and differentiation of hematopoietic cells[J]. Blood, 2000, 96(6): 2116-2124. [26]Saigusa S, Tanaka K, Mohri Y, et al. Clinical significance of RacGAP1 expression at the invasive front of gastric cancer[J]. Gastric Cancer, 2015, 18(1): 84-92. [27]Liang Y, Liu M, Wang P, et al. Analysis of 20 genes at chromosome band 12q13: RACGAP1 and MCRS1 overexpression in nonsmall-cell lung cancer[J]. Genes Chromosomes Cancer, 2013, 52(3): 305-315. [28]潘 章, 陈 静, 耿轶钊, 等. 驱动蛋白的颈链结构与功能关系 [J]. 生命科学研究, 2014, 18(3): 255-259. [29]Chen J, Li S, Zhou S, et al. Kinesin superfamily protein expression and its association with progression and prognosis in hepatocellular carcinoma[J]. J Cancer Res Ther, 2017, 13(4): 651-659. [30]Yang T, Zhang XB, Zheng ZM. Suppression of KIF14 expression inhibits hepatocellular carcinoma progression and predicts favorable outcome[J]. Cancer Sci, 2013,104(5): 552-557. [31]Liao W, Huang G, Liao Y, et al. High KIF18A expression correlates with unfavorable prognosis in primary hepatocellular carcinoma[J]. Oncotarget, 2014, 5(21): 10271-10279. |